Australia-wide dispatch

Quantified
Peptides
Ipamorelin 10mg — research peptide, lyophilised powder in a glass vial, supplied by Quantified Peptides, Sydney, Australia. For in-vitro research use only.

Peptides

Ipamorelin

Ipamorelin (NNC 26-0161). Supplied as a lyophilised powder in 10mg vials.

Supplied as lyophilised powder in a 10mg specification. Storage: -20°C · Keep dry, avoid light. Dispatched from Sydney, Australia-wide.

Product information

About Ipamorelin

Ipamorelin (NNC 26-0161)

Research background as published in the scientific literature. Supplied for in-vitro laboratory research only; nothing here is a claim about use in humans or animals.

Ipamorelin (NNC 26-0161) is a synthetic pentapeptide developed by Novo Nordisk that acts as a selective growth hormone secretagogue receptor 1a (GHS-R1a) agonist. It was developed as an improvement over earlier GH secretagogues (GHRP-2, GHRP-6) due to its high receptor selectivity.

Research has demonstrated that Ipamorelin stimulates GH release with high selectivity, showing minimal effects on cortisol, prolactin, or ACTH compared to earlier GHRPs. This selectivity profile makes it a widely used research tool for investigating GH secretory dynamics and pituitary function.

Type
Pentapeptide GHS-R1a agonist
Research Areas
GH secretion, pulsatile GH release, endocrine research
Amino Acids
5 residues (pentapeptide)
Target
GHS-R1a (ghrelin receptor)
Molecular Weight
711 Da
CAS Number
170851-70-4
Selectivity
High — minimal cortisol/prolactin
Half-life
~2 hours
Developer
Novo Nordisk (NNC 26-0161)
  1. 01Selective GHS-R1a AgonismIpamorelin is a highly selective agonist of the growth hormone secretagogue receptor 1a (GHS-R1a). Unlike GHRP-6, research has shown it stimulates GH release with minimal co-stimulation of cortisol, prolactin, or ACTH.
  2. 02Pulsatile GH ReleaseLaboratory and clinical research has examined Ipamorelin's ability to stimulate pulsatile GH release that closely mimics endogenous GH secretion patterns, making it a tool for studying physiological GH dynamics.
  3. 03Synergistic CombinationResearch has investigated Ipamorelin in combination with GHRH analogues such as CJC-1295 NO DAC, examining whether dual-pathway stimulation (GHS-R1a + GHRH-R) produces additive or synergistic GH release in research models.

References

  1. 1Raun K et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998;139(5):552-561.
  2. 2Bowers CY. Unnatural growth hormone-releasing peptide. J Clin Endocrinol Metab. 1998;83(9):3003-3006.
  3. 3PubMed: pubmed.ncbi.nlm.nih.gov/?term=Ipamorelin+GH+secretagogue
  4. 4Johansen PB et al. Ipamorelin, a new growth-hormone-releasing peptide, induces longitudinal bone growth. Growth Horm IGF Res. 1999;9(2):106-113.

Ships from Sydney

Australia-wide, plain unbranded packaging. Dispatched on business days.

If it arrives wrong

Replaced, resent or refunded. You do not have to argue for it.

Also in this range.

Compounds the supplier files alongside this one.

View the range